Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 18, 2013

Covance Expands Pathology Offering with NeoGenomics Collab

  • Covance and NeoGenomics entered a collaboration to provide comprehensive anatomic pathology and specialty laboratory testing services for global clinical trials.

    Through the alliance, Covance's clients will gain access to fully integrated anatomic pathology and histology (APH) services, including immunohistochemistry, fluorescence in-situ hybridization, and molecular testing. The company will establish a laboratory at NeoGenomics' Fort Myers, FL facility and, together with NeoGenomics, will provide a range of APH, tissue-based biomarkers, and other specialty testing services. The firms will then expand joint capabilities at Covance's central laboratory locations in Shanghai, China; Geneva, Switzerland; and Singapore.

    Additionally, Covance will have access to NeoGenomics' extensive medical and scientific networks, which include more than 500 pathologists, according to the company. Covance's market reach, established client relationships, and clinical trials experience will also be available to Neogenomics.

    "The collaboration with NeoGenomics will offer our clients fully integrated anatomic pathology services from sample preparation, staining and imaging, to pathology interpretation by leading pathologists, in an end-to-end manner," said Paul Kirchgraber, M.D., vice president of laboratory operations and medical affairs, Covance Central Laboratory Services. "Providing these integrated services through the Covance laboratory co-located within NeoGenomics results in improved turnaround times critical to oncology clinical trials."



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »